How did Newkin's revenue and expenses trend in Q2 2025?

Newkin's revenue and expenses trends in Q2 2025 are not currently available. However, we can infer some general patterns from similar reports in the industry:

1. **Revenue Trends**: Global Payments (GPN) reported a dip in revenue for Q1 2025, which was partly due to a realignment of business structure and operating model. In contrast, Knowles Corporation (KN) reported a slight increase in revenue for Q1 2025, with medtech and specialty audio segments showing growth. Adaptive Biotechnologies (ADPT) demonstrated strong revenue growth in Q1 2025, driven by the Minimal Residual Disease (MRD) segment, which saw a 34% increase in revenue.
2. **Expense Trends**: Global Payments' operating expenses climbed in Q1 2025, which may indicate increased costs associated with restructuring and integrating acquisitions. Knowles Corporation's operating expenses decreased slightly, showing improved financial discipline. Adaptive Biotechnologies reduced operating expenses by 9% year-over-year, reflecting efforts towards operational efficiency.

Given these examples, it's reasonable to assume that Newkin's revenue may have shown growth, especially given the positive trends in the medtech and specialty audio segments. Expenses, on the other hand, might have been relatively stable or even decreased due to cost-control measures, similar to Adaptive Biotechnologies. However, without specific data, these inferences are based on industry trends and should be confirmed with Newkin's financial reports or statements.